MARKET

FBRX

FBRX

Forte Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.20
-2.57
-7.18%
Closed 17:39 04/20 EDT
OPEN
35.28
PREV CLOSE
35.77
HIGH
35.49
LOW
32.37
VOLUME
159.83K
TURNOVER
--
52 WEEK HIGH
53.99
52 WEEK LOW
13.35
MARKET CAP
448.49M
P/E (TTM)
-3.0250
1D
5D
1M
3M
1Y
5Y
Citi initiates Forte Biosciences with a buy, sees 159% upside
Citi analyst Mohit Bansal has initiated Forte Biosciences (FBRX) with a buy rating and a $75 price target.Given yesterday's closing price of $28.92, that represents an upside of ~159%.Bansal's rating
Seekingalpha · 03/26 14:35
DJ Forte Biosciences Initiated at Buy by Citigroup
Dow Jones · 03/26 12:43
DJ Forte Biosciences Price Target Announced at $75.00/Share by Citigroup
Dow Jones · 03/26 12:43
Citigroup Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $75
Citigroup analyst Mohit Bansal initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announces Price Target of $75.
Benzinga · 03/26 12:33
Aspira extends gains as analysts weigh in; Flexion to benefit from Pfizer’s failure in osteoarthritis drug and more in today’s analyst action
Aspira Women's Health (AWH) has extended the post-market gains with a ~12.2% rise in the pre-market as analysts weigh in on its new agreement to develop an early detection test for ovarian cancer.“We
Seekingalpha · 03/26 12:20
Forte Posts Lower-Than-Feared Quarterly Loss; Shares Drop 9.5%
Forte Biosciences reported a smaller-than-expected loss in the fourth quarter. Shares of the clinical-stage biopharmaceutical company rose almost 2% in Wednesday’s extended trading session after closing 9.5% lower on the day. Forte (FBRX) incurred a loss o...
SmarterAnalyst · 03/25 12:42
Forte Biosciences (FBRX) Received its Third Buy in a Row
After Chardan Capital and Ladenburg Thalmann & Co. gave Forte Biosciences (NASDAQ: FBRX) a Buy rating last month, the company received another Buy,
SmarterAnalyst · 03/24 19:05
Ladenburg Thalmann & Co. Keeps a Buy Rating on Forte Biosciences (FBRX)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Forte Biosciences (FBRX), with a price target of
SmarterAnalyst · 03/24 17:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FBRX. Analyze the recent business situations of Forte Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FBRX stock price target is 88.60 with a high estimate of 105.00 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 115
Institutional Holdings: 11.24M
% Owned: 83.22%
Shares Outstanding: 13.51M
TypeInstitutionsShares
Increased
19
821.78K
New
15
1.30M
Decreased
8
430.29K
Sold Out
12
101.37K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
+0.33%
Key Executives
Chairman/Independent Director
faheem Hasnain
Chairman/President/Chief Executive Officer/Director
Paul Wagner
Chief Financial Officer
Antony Riley
Senior Vice President
Fairooz Kabbinavar
Director
Thomas Darcy
Director
Lawrence Eichenfield
Director
Steven Kornfeld
Director
Patricia Walker
Director
Donald Williams
No Data
  • All
  • Financials
  • Insiders
More
About FBRX
Forte Biosciences, Inc., formerly Tocagen Inc., is a clinical-stage biopharmaceutical company. The Company is focused on clinical program and developing a live biotherapeutic for the treatment of inflammatory skin diseases, particularly for pediatric atopic dermatitis patients. It provides FB-401, which is a live biotherapeutic for the treatment of inflammatory skin diseases. FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.

Webull offers kinds of Forte Biosciences Inc stock information, including NASDAQ:FBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FBRX stock methods without spending real money on the virtual paper trading platform.